IRLAB Therapeutics AB (publ) (IRLAB-A) - Total Liabilities

Latest as of September 2025: Skr116.34 Million SEK ≈ $12.52 Million USD

Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has total liabilities worth Skr116.34 Million SEK (≈ $12.52 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IRLAB Therapeutics AB (publ) (IRLAB-A) cash flow conversion to assess how effectively this company generates cash.

IRLAB Therapeutics AB (publ) - Total Liabilities Trend (2013–2024)

This chart illustrates how IRLAB Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are IRLAB Therapeutics AB (publ)'s assets to evaluate the company's liquid asset resilience ratio.

IRLAB Therapeutics AB (publ) Competitors by Total Liabilities

The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
Emova Group SA PA:ALEMV	France	€42.01 Million
Bionano Genomics Inc NASDAQ:BNGO	USA	$29.16 Million
Hindcon Chemicals Limited NSE:HINDCON	India	Rs154.06 Million
Pearl Gold AG F:02P	Germany	€531.93K
Maxeon Solar Technologies Ltd NASDAQ:MAXN	USA	$507.96 Million
Skin Elements Ltd AU:SKN	Australia	AU$429.34K
Pan Malaysia Corporation Bhd KLSE:4081	Malaysia	RM144.80 Million
Platinex Inc F:9PX	Germany	€1.91 Million

Liability Composition Analysis (2013–2024)

This chart breaks down IRLAB Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IRLAB Therapeutics AB (publ) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.30	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	1.22	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.15	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.68	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how IRLAB Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for IRLAB Therapeutics AB (publ) (2013–2024)

The table below shows the annual total liabilities of IRLAB Therapeutics AB (publ) from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr103.58 Million ≈ $11.15 Million	+68.81%
2023-12-31	Skr61.36 Million ≈ $6.60 Million	+87.50%
2022-12-31	Skr32.72 Million ≈ $3.52 Million	-55.15%
2021-12-31	Skr72.97 Million ≈ $7.85 Million	+228.86%
2020-12-31	Skr22.19 Million ≈ $2.39 Million	-15.44%
2019-12-31	Skr26.24 Million ≈ $2.82 Million	+110.59%
2018-12-31	Skr12.46 Million ≈ $1.34 Million	+56.32%
2017-12-31	Skr7.97 Million ≈ $857.81K	-13.57%
2016-12-31	Skr9.22 Million ≈ $992.54K	+1.74%
2015-12-31	Skr9.06 Million ≈ $975.54K	-49.23%
2014-12-31	Skr17.86 Million ≈ $1.92 Million	+254971.43%
2013-12-31	Skr7.00K ≈ $753.31	--

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$12.86 Million

Skr119.48 Million SEK

Market Cap Rank

#26241 Global

#563 in Sweden

Share Price

Skr1.41

Change (1 day)

-0.85%

52-Week Range

Skr1.41 - Skr7.58

All Time High

Skr104.95